Alumis’ (ALMS) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Alumis (NASDAQ:ALMS) in a report published on Friday,Benzinga reports. The firm currently has a $25.00 price target on the stock.

ALMS has been the subject of several other reports. Citigroup reissued a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. Morgan Stanley reaffirmed an “overweight” rating and set a $39.00 price objective on shares of Alumis in a report on Friday, May 15th. Wells Fargo & Company raised their target price on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Guggenheim boosted their target price on shares of Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Finally, Wall Street Zen cut shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Alumis has a consensus rating of “Moderate Buy” and a consensus target price of $40.30.

Alumis Price Performance

ALMS stock opened at $25.31 on Friday. The company has a fifty day moving average price of $26.19 and a 200 day moving average price of $25.27. Alumis has a 12 month low of $3.76 and a 12 month high of $31.35. The company has a market cap of $3.23 billion, a price-to-earnings ratio of -6.56 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative net margin of 5,933.46% and a negative return on equity of 95.08%. The company had revenue of $1.66 million during the quarter, compared to analyst estimates of $3.65 million. As a group, analysts anticipate that Alumis will post -2.87 earnings per share for the current year.

Insider Activity

In related news, insider Sanam Pangali sold 1,364 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $35,968.68. Following the completion of the transaction, the insider owned 9,747 shares of the company’s stock, valued at approximately $257,028.39. The trade was a 12.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David M. Goldstein sold 2,596 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $68,456.52. Following the sale, the insider directly owned 30,970 shares in the company, valued at $816,678.90. This represents a 7.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 19,953 shares of company stock worth $534,311 in the last quarter. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On Alumis

Institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System boosted its holdings in Alumis by 2,222.5% in the 1st quarter. California State Teachers Retirement System now owns 80,845 shares of the company’s stock worth $1,781,000 after acquiring an additional 77,364 shares during the period. First Trust Advisors LP bought a new position in Alumis during the first quarter worth $1,456,000. The Manufacturers Life Insurance Company boosted its position in Alumis by 775.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 154,634 shares of the company’s stock valued at $3,407,000 after purchasing an additional 136,973 shares during the period. Swiss National Bank bought a new position in shares of Alumis during the first quarter worth about $2,815,000. Finally, Elmind Capital LP bought a new stake in Alumis in the 1st quarter valued at about $2,864,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.